Get the Stockscreener App
12.28
5.05%
0.59
CorMedix Inc stock is traded at $12.28, with a volume of 1.42M.
It is up +5.05% in the last 24 hours and up +63.30% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$11.69
Open:
$11.65
24h Volume:
1.42M
Relative Volume:
0.81
Market Cap:
$832.95M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-13.35
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
+5.32%
1M Performance:
+63.30%
6M Performance:
+18.88%
1Y Performance:
+136.15%
1-Day Range:
$11.65
$12.33
1-Week Range:
$11.21
$12.33
52-Week Range:
$3.61
$13.85
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.28 | 790.84M | 65,400 | -46.34M | -38.74M | -0.92 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
CorMedix Inc. to Participate in the RBC Global Healthcare Conference - The Manila Times
CorMedix Inc. to Participate in RBC Capital Markets Global Healthcare Conference on May 21, 2025 - Nasdaq
Leading Biopharma CorMedix Set for Key Presentation at RBC Healthcare Conference Next Week - Stock Titan
CorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement - ACCESS Newswire
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock - Yahoo Finance
Market Highlights: CorMedix Inc (CRMD) Ends on a High Note at 12.03 - DWinneX
CorMedix Inc. Just Recorded A 22% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
CorMedix Inc. (CRMD): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential - Insider Monkey
Cormedix anticipates Q2 revenue at high end of $23M-$31M range with inpatient growth accelerating - MSN
Cormedix (CRMD) Receives a Buy from RBC Capital - The Globe and Mail
CorMedix at Citizens JMP: Strategic Growth and Market Expansion By Investing.com - Investing.com Nigeria
CorMedix at Citizens JMP: Strategic Growth and Market Expansion - Investing.com
CorMedix Inc. (NASDAQ:CRMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Just Shipped A Substantial Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Estimates - Yahoo Finance
CorMedix Inc. Reports Strong Q1 Earnings and Positive Outlook - MSN
(CRMD) Investment Analysis - news.stocktradersdaily.com
CorMedix stock rises after earnings, revenue beat - MSN
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises - Investing.com Nigeria
Cormedix Inc (CRMD) Q1 2025 Earnings Call Highlights: Record Profitability and Strategic Growth ... By GuruFocus - Investing.com Canada
CorMedix Inc. Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: CorMedix Q1 2025 results beat expectations, stock rises By Investing.com - Investing.com South Africa
CorMedix: Q1 Earnings Snapshot - Norwalk Hour
CorMedix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRMD Price Target Increased as Positive Momentum Builds | CRMD S - GuruFocus
CorMedix Shares Soar After Q1 Earnings, Revenue Beat Consensus - marketscreener.com
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025 - The Globe and Mail
Cormedix Inc (CRMD) Q1 2025 Earnings: EPS of $0.32 Beats Estimat - GuruFocus
CorMedix (CRMD) Surpasses Revenue and EPS Expectations in Q1 - GuruFocus
CRMD Price Target Increased as Positive Momentum Builds | CRMD Stock News - GuruFocus
CorMedix Inc. Revises Sales Guidance for the First Half of 2025 - marketscreener.com
CorMedix (CRMD) Surges on Strong Q1 Earnings - GuruFocus
CorMedix Inc (NASDAQ: CRMD): Hidden Gems In A Time Of Volatility - Stocksregister
CRMD Stock Rating and Price Target Maintained by Analyst | CRMD - GuruFocus
CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed - Asianet Newsable
CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed By Stocktwits - Investing.com India
CorMedix stock rises as Q1 earnings and revenue surpass estimates By Investing.com - Investing.com Nigeria
CorMedix stock rises as Q1 earnings and revenue surpass estimates - Investing.com Australia
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
CorMedix Inc. Reports Q1 2025 Financial Results: $39.1 Million in Net Revenue and Positive Adjusted EBITDA of $23.6 Million - Nasdaq
CorMedix Hits Major Milestone: Reports First Ever Profitable Quarter with $39.1M Revenue, Raises Guidance - Stock Titan
Cormedix Inc (CRMD) Q1 2025: Everything You Need To Know Ahead O - GuruFocus
Market Momentum Report: CorMedix Inc (CRMD)’s Positive Close at 9.65 - DWinneX
CorMedix Inc expected to post earnings of 25 cents a shareEarnings Preview - TradingView
Investors in cash trouble should check out CorMedix Inc (CRMD) - Sete News
The CorMedix Inc (CRMD) had a good session last reading, didn’t it? - uspostnews.com
Investing in CorMedix Inc (CRMD): What You Must Know - knoxdaily.com
CorMedix Inc. to Announce First Quarter 2025 Financial Results and Corporate Update on May 6, 2025 - Nasdaq
Cormedix To Report First Quarter 2025 Financial Results - marketscreener.com
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):